These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Current management of myelodysplastic syndromes]. Vey N; Charbonnier A Rev Prat; 2010 Dec; 60(10):1416-9. PubMed ID: 21425543 [TBL] [Abstract][Full Text] [Related]
43. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Balducci L Cancer; 2006 May; 106(10):2087-94. PubMed ID: 16607649 [TBL] [Abstract][Full Text] [Related]
44. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. Beran M Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661 [TBL] [Abstract][Full Text] [Related]
46. An update on treatment of higher risk myelodysplastic syndromes. Rahmé R; Adès L Expert Rev Hematol; 2019 Jan; 12(1):61-70. PubMed ID: 30334467 [TBL] [Abstract][Full Text] [Related]
47. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies. Wang C; Yang Y; Gao S; Chen J; Yu J; Zhang H; Li M; Zhan X; Li W Crit Rev Oncol Hematol; 2018 Feb; 122():123-132. PubMed ID: 29458780 [TBL] [Abstract][Full Text] [Related]
48. Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings. Uy N; Singh A; Gore SD; Prebet T Expert Opin Pharmacother; 2017 Aug; 18(12):1213-1224. PubMed ID: 28675065 [TBL] [Abstract][Full Text] [Related]
49. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E; Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483 [TBL] [Abstract][Full Text] [Related]
50. Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes. Wang C; Sallman DA Curr Treat Options Oncol; 2023 May; 24(5):387-408. PubMed ID: 36966266 [TBL] [Abstract][Full Text] [Related]
51. Therapeutic strategies in low and high-risk MDS: What does the future have to offer? Scalzulli E; Pepe S; Colafigli G; Breccia M Blood Rev; 2021 Jan; 45():100689. PubMed ID: 32253020 [TBL] [Abstract][Full Text] [Related]
52. Myelodysplastic syndromes: moving towards personalized management. Hellström-Lindberg E; Tobiasson M; Greenberg P Haematologica; 2020 Jul; 105(7):1765-1779. PubMed ID: 32439724 [TBL] [Abstract][Full Text] [Related]
53. Treatment of MDS: something old, something new, something borrowed.. Sekeres MA Hematology Am Soc Hematol Educ Program; 2009; ():656-63. PubMed ID: 20008251 [TBL] [Abstract][Full Text] [Related]
54. Management of patients with lower-risk myelodysplastic syndromes. Brunner AM; Leitch HA; van de Loosdrecht AA; Bonadies N Blood Cancer J; 2022 Dec; 12(12):166. PubMed ID: 36517487 [TBL] [Abstract][Full Text] [Related]
60. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Shallis RM; Chokr N; Stahl M; Pine AB; Zeidan AM Expert Rev Hematol; 2018 Sep; 11(9):715-726. PubMed ID: 30024293 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]